Chris Schott
Stock Analyst at JP Morgan
(3.52)
# 859
Out of 4,937 analysts
133
Total ratings
56.18%
Success rate
2.72%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRGO Perrigo Company | Maintains: Overweight | $38 → $35 | $22.55 | +55.21% | 12 | Aug 7, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $550 → $675 | $658.06 | +2.57% | 8 | Aug 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $563.00 | +42.10% | 8 | Jun 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $16.37 | +40.50% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $130.67 | +33.93% | 4 | May 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $119.41 | +8.87% | 6 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $8.54 | +40.52% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $198.05 | +0.98% | 2 | Nov 13, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $147.35 | +56.09% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $625.65 | +75.82% | 20 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $20 | $9.22 | +116.92% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $37.58 | +11.76% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $288.23 | -6.32% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.58 | +38.32% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $80.69 | +54.91% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $9.70 | +44.33% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.82 | +1,239.99% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $16.67 | +19.98% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.75 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $45.95 | +69.75% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $7.42 | +12,703.23% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.06 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.20 | +98.41% | 3 | Nov 2, 2018 |
Perrigo Company
Aug 7, 2025
Maintains: Overweight
Price Target: $38 → $35
Current: $22.55
Upside: +55.21%
IDEXX Laboratories
Aug 4, 2025
Maintains: Overweight
Price Target: $550 → $675
Current: $658.06
Upside: +2.57%
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $563.00
Upside: +42.10%
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $16.37
Upside: +40.50%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $130.67
Upside: +33.93%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $119.41
Upside: +8.87%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.54
Upside: +40.52%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $198.05
Upside: +0.98%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $147.35
Upside: +56.09%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $625.65
Upside: +75.82%
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.22
Upside: +116.92%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $37.58
Upside: +11.76%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $288.23
Upside: -6.32%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.58
Upside: +38.32%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $80.69
Upside: +54.91%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $9.70
Upside: +44.33%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.82
Upside: +1,239.99%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $16.67
Upside: +19.98%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.75
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $45.95
Upside: +69.75%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $7.42
Upside: +12,703.23%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.06
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.20
Upside: +98.41%